Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.055 CHF | -6.78% | -8.03% | +34.15% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
Sales 2021 | 331 361.65 | Sales 2022 | 1.48M 1.61M | Capitalization | 19.96M 21.81M |
---|---|---|---|---|---|
Net income 2021 | -11M -12.02M | Net income 2022 | -18M -19.67M | EV / Sales 2021 * | - |
Net cash position 2021 | 6.23M 6.81M | Net Debt 2022 | 4.23M 4.63M | EV / Sales 2022 | 16.4 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.07
x | Employees | 28 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 46.61% |
Latest transcript on Spexis AG
1 day | -6.78% | ||
1 week | -8.03% | ||
Current month | -35.29% | ||
1 month | -28.57% | ||
3 months | -80.22% | ||
6 months | -73.81% | ||
Current year | +34.15% |
Managers | Title | Age | Since |
---|---|---|---|
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 21-12-29 |
Martin Jakobovic
DFI | Director of Finance/CFO | - | - |
Stephan Wehselau
COO | Chief Operating Officer | 55 | 21-12-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Hartman
BRD | Director/Board Member | 62 | 21-12-29 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 21-12-29 |
Kuno Sommer
BRD | Director/Board Member | 68 | 12-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 0.055 | -6.78% | 70 500 |
24-04-23 | 0.059 | +2.43% | 166,217 |
24-04-22 | 0.0576 | +4.73% | 158,616 |
24-04-19 | 0.055 | +6.59% | 37,501 |
24-04-18 | 0.0516 | -13.71% | 117,601 |
Delayed Quote Swiss Exchange, April 24, 2024 at 05:48 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+34.15% | 4.38M | |
-2.86% | 87.37B | |
+4.08% | 41.01B | |
-25.35% | 28.08B | |
+54.18% | 24.72B | |
-4.52% | 17.47B | |
-42.09% | 11.69B | |
-17.77% | 11.6B | |
-12.10% | 11.56B | |
+1.50% | 8.44B |
- Stock Market
- Equities
- POLN Stock